Interlaboratory analysis of isavuconazole ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Interlaboratory analysis of isavuconazole plasma concentration assays among european laboratories
Auteur(s) :
Pea, Federico [Auteur]
Ospedale "Santa Maria della Misericordia" = University Hospital "Santa Maria della Misericordia"
Krause, Robert [Auteur]
Medical University of Graz = Medizinische Universität Graz
Muller, Carsten [Auteur]
University Hospital of Cologne [Cologne]
Hennart, Benjamin [Auteur]
Toxicologie et Génopathies [CHRU Lille]
Richardson, Malcolm [Auteur]
Manchester University NHS Foundation Trust [MFT]
Meinitzer, Andreas [Auteur]
Medical University of Graz = Medizinische Universität Graz
Wiesen, Martin H. J. [Auteur]
University Hospital of Cologne [Cologne]
Wiktorowicz, Tatiana [Auteur]
Spickermann, Jochen [Auteur]
Henriksen, Anne S. [Auteur]
Ospedale "Santa Maria della Misericordia" = University Hospital "Santa Maria della Misericordia"
Krause, Robert [Auteur]
Medical University of Graz = Medizinische Universität Graz
Muller, Carsten [Auteur]
University Hospital of Cologne [Cologne]
Hennart, Benjamin [Auteur]
Toxicologie et Génopathies [CHRU Lille]
Richardson, Malcolm [Auteur]
Manchester University NHS Foundation Trust [MFT]
Meinitzer, Andreas [Auteur]
Medical University of Graz = Medizinische Universität Graz
Wiesen, Martin H. J. [Auteur]
University Hospital of Cologne [Cologne]
Wiktorowicz, Tatiana [Auteur]
Spickermann, Jochen [Auteur]
Henriksen, Anne S. [Auteur]
Titre de la revue :
Therapeutic Drug Monitoring
Nom court de la revue :
Ther Drug Monit
Numéro :
41
Pagination :
657-664
Éditeur :
Lippincott, Williams & Wilkins
Date de publication :
2019-10-01
ISSN :
1536-3694
Mot(s)-clé(s) en anglais :
LC-UV
LC-FL
LC-MS/MS
isavuconazole
bioassay
LC-FL
LC-MS/MS
isavuconazole
bioassay
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Under certain circumstances, clinicians treating patients with isavuconazole for invasive aspergillosis or mucormycosis may use therapeutic drug monitoring. However, the accuracy and reproducibility of the various assays ...
Lire la suite >Under certain circumstances, clinicians treating patients with isavuconazole for invasive aspergillosis or mucormycosis may use therapeutic drug monitoring. However, the accuracy and reproducibility of the various assays used by different laboratories for the quantification of isavuconazole plasma concentrations have yet to be determined. Human plasma samples spiked with known concentrations of isavuconazole were provided to 27 European laboratories that took part in a "round-robin" test (an interlaboratory test performed independently at least 2 times; 2 rounds performed in the current study). Assay methods included liquid chromatography-tandem mass spectrometry (LC-MS/MS), LC with ultraviolet detection (LC-UV), LC with fluorescence detection (LC-FL), and bioassay. The accuracy and reproducibility compared with the known concentrations for each sample in each round were compared overall, between assays, and between laboratories. Twenty-seven laboratories participated in the study (LC-MS/MS, n = 15; LC-UV; n = 9; LC-FL, n = 1; bioassay, n = 2). In round 1, for nominal concentrations of 1000, 1700, 2500, and 4000 ng/mL, the mean (SD) determined concentrations were 1007 (183), 1710 (323), 2528 (540), and 3898 (842) ng/mL, respectively. In round 2, for nominal concentrations of 1200, 1800, 2400, and 4000 ng/mL, the mean (SD) determined concentrations were 1411 (303), 2111 (409), 2789 (511), and 4723 (798) ng/mL, respectively. Over both rounds, determined concentrations were consistently within 15% of the nominal concentrations for 10 laboratories (LC-MS/MS, n = 4; LC-UV, n = 5; bioassay, n = 1) and consistently exceeded the upper 15% margin for 7 laboratories (LC-MS/MS and LC-UV, n = 3 each; LC-FL, n = 1). Alignment of methodologies among laboratories may be warranted to improve the accuracy and reproducibility of therapeutic drug measurements.Lire moins >
Lire la suite >Under certain circumstances, clinicians treating patients with isavuconazole for invasive aspergillosis or mucormycosis may use therapeutic drug monitoring. However, the accuracy and reproducibility of the various assays used by different laboratories for the quantification of isavuconazole plasma concentrations have yet to be determined. Human plasma samples spiked with known concentrations of isavuconazole were provided to 27 European laboratories that took part in a "round-robin" test (an interlaboratory test performed independently at least 2 times; 2 rounds performed in the current study). Assay methods included liquid chromatography-tandem mass spectrometry (LC-MS/MS), LC with ultraviolet detection (LC-UV), LC with fluorescence detection (LC-FL), and bioassay. The accuracy and reproducibility compared with the known concentrations for each sample in each round were compared overall, between assays, and between laboratories. Twenty-seven laboratories participated in the study (LC-MS/MS, n = 15; LC-UV; n = 9; LC-FL, n = 1; bioassay, n = 2). In round 1, for nominal concentrations of 1000, 1700, 2500, and 4000 ng/mL, the mean (SD) determined concentrations were 1007 (183), 1710 (323), 2528 (540), and 3898 (842) ng/mL, respectively. In round 2, for nominal concentrations of 1200, 1800, 2400, and 4000 ng/mL, the mean (SD) determined concentrations were 1411 (303), 2111 (409), 2789 (511), and 4723 (798) ng/mL, respectively. Over both rounds, determined concentrations were consistently within 15% of the nominal concentrations for 10 laboratories (LC-MS/MS, n = 4; LC-UV, n = 5; bioassay, n = 1) and consistently exceeded the upper 15% margin for 7 laboratories (LC-MS/MS and LC-UV, n = 3 each; LC-FL, n = 1). Alignment of methodologies among laboratories may be warranted to improve the accuracy and reproducibility of therapeutic drug measurements.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Institut Pasteur de Lille
Université de Lille
Institut Pasteur de Lille
Université de Lille
Collections :
Date de dépôt :
2022-02-02T10:24:23Z
2024-02-20T13:27:55Z
2024-02-20T13:27:55Z
Fichiers
- Pea et al.pdf
- Version éditeur
- Accès libre
- Accéder au document